{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:03:41Z","timestamp":1787321021212,"version":"build-2736575974"},"reference-count":82,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Cabinet for Health and Family Services\u2019 Department for Medicaid Services"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Am Psychiatr Nurses Assoc"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Using long-acting injectable (LAI) antipsychotic medications can improve the outcomes of patients with schizophrenia, such as reducing symptom severity and hospitalization risk. However, the outcomes of switching from oral to LAI antipsychotic medications are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The purpose of this review is to provide a summary of the clinical, quality of life, and health care utilization outcomes of switching from oral to LAI antipsychotics among patients with Schizophrenia Spectrum Disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We thoroughly searched the PubMed, Scopus, PsycInfo, and CINAHL databases. To conduct the meta-analysis, we used the Comprehensive Meta-Analysis Program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Forty-one articles met our inclusion criteria. After switching to LAIs, symptom severity, the number of rehospitalizations, emergency department visits, and overall health care costs were reduced. Also, social functioning significantly improved. However, no differences were observed in the frequency of outpatient visits. Pharmacy costs were increased between pre- and post-LAI initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings support evidence that changing the route of administration of antipsychotic medications from oral to long-acting intramuscular injections can improve the clinical, quality of life, and health care utilization outcomes in people with schizophrenia. Health care practitioners might consider encouraging LAI use earlier during treatment for schizophrenia for better clinical outcomes and to reduce health care utilization associated with treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10783903241279605","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T08:08:38Z","timestamp":1729670918000},"page":"138-164","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical, Quality of Life, and Health Care Utilization Outcomes of Switching the Administration Route of Antipsychotic Medications Among People With Schizophrenia Spectrum Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-4549","authenticated-orcid":false,"given":"Amani","family":"Kappi","sequence":"first","affiliation":[{"name":"Amani Kappi, PhD, MSN, RN, BSN, Jazan University, Jazan, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianyi Wang, MS, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassema","family":"Abu Farsakh","sequence":"additional","affiliation":[{"name":"Bassema Abu Farsakh, PhD, MSN, BSN, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5674-6253","authenticated-orcid":false,"given":"Chizimuzo T. C.","family":"Okoli","sequence":"additional","affiliation":[{"name":"Chizimuzo T. C. Okoli, PhD, MPH, MSN, APRN, PMHNP-BC, University of Kentucky, Lexington, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"1","key":"e_1_3_2_2_1","first-page":"15","article-title":"Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale","volume":"9","author":"Allen M. H.","year":"2012","unstructured":"Allen M. H., Daniel D. G., Revicki D. A., Canuso C. M., Turkoz I., Fu D. J., Lindenmayer J. P. (2012). Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale. Innovations in Clinical Neuroscience, 9(1), 15\u201324.","journal-title":"Innovations in Clinical Neuroscience"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696990701646825"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Beauclair L. Lam A. McCormick J. Luong D. Camacho F. (2005). Impact of Risperidone long-acting injectable on hospitalization and medication use in patients with schizophrenia. CORE PMH23. https:\/\/core.ac.uk\/download\/pdf\/82324872.pdf","DOI":"10.1016\/S1098-3015(10)67769-8"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0507-x"},{"key":"e_1_3_2_6_1","author":"Borenstein M.","year":"2013","unstructured":"Borenstein M., Hedges L., Higgins J., Rothstein H. (2013). Comprehensive Meta-Analysis Version 3 (CMA). SAS Institute Inc.","journal-title":"Comprehensive Meta-Analysis Version 3 (CMA)"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/13651509809115373"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.11.010"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.02.019"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-168"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-992140"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Denham J. Adamson L. (1973). Long-acting phenothiazines in the prevention of relapse of schizophrenic patients. Canadian Psychiatric Association Journal 18(3) 235\u2013237.","DOI":"10.1177\/070674377301800311"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001133"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Di Lorenzo R. Cameli M. Piemonte C. Bolondi M. Landi G. Pollutri G. Spattini L. Moretti V. Ferri P. (2018). Clinical improvement relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting. Nordic Journal of Psychiatry 72(3) 214\u2013220.","DOI":"10.1080\/08039488.2017.1420819"},{"issue":"449","key":"e_1_3_2_15_1","first-page":"89","article-title":"A nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis","volume":"95","author":"Duval S.","year":"2000","unstructured":"Duval S., Tweedie R. (2000). A nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis. Journal of the American Statistical Association, 95(449), 89\u201398.","journal-title":"Journal of the American Statistical Association"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S142634"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Enatescu V. R. Dehelean C. A. Nussbaum L. A. Hogea L. Homorogan C. Enatescu I. Papava I. Marinescu I. Ifteni P. Simu M. Catalin M. Giurgi-Oncu C. Sirbu I. O. (2020). Study on tolerability and efficacy of paliperidone palmitate olanzapine pamoate and risperidone long acting injection in a Romanian sample of patients with schizophrenia. Farmacia 68(2) 242\u2013249.","DOI":"10.31925\/farmacia.2020.2.8"},{"key":"e_1_3_2_19_1","first-page":"86","volume-title":"Handbook of psychiatric measures","author":"Endicott J.","year":"2008","unstructured":"Endicott J., Spitzer R. L., Fleiss J. L. (2008). Global assessment scale (GAS), global assessment of functioning (GAF) scale, social and occupational functioning assessment scale (SOFAS). In Rush A. J., First M. B., Blacker D. B. (Eds.), Handbook of psychiatric measures (2nd ed., pp. 86\u201390). American Psychiatric Publishing, Inc.","edition":"2"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21r14153"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.09.041"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903303902"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Girardi P. Serafini G. Pompili M. Innamorati M. Tatarelli R. Baldessarini R. J. (2010). Prospective open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 43(2) 66\u201372.","DOI":"10.1055\/s-0029-1239541"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Haddad P. M. Brain C. Scott J. (2014). Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Related Outcome Measures 5(5) 43\u201362. https:\/\/doi.org\/10.2147\/PROM.S42735","DOI":"10.2147\/PROM.S42735"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.05.095"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8810"},{"key":"e_1_3_2_27_1","unstructured":"Johnson D. A. Freeman H. (1972). Long-acting tranquillizers. The Practitioner 208(245) 395\u2013400."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212267"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000452"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Kane J. M. Zhao C. Johnson B. R. Baker R. A. Eramo A. McQuade R. D. Duca A. R. Sanchez R. Peters-Strickland T. (2015). Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: Final efficacy analysis. Journal of Medical Economics 18(2) 145\u2013154.","DOI":"10.3111\/13696998.2014.979936"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(88)90038-8"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2019.052"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08440"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Kishimoto T. Hagi K. Kurokawa S. Kane J. M. Correll C. U. (2021). Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised cohort and pre-post studies. The Lancet Psychiatry 8(5) 387\u2013404. https:\/\/doi.org\/10.1016\/S2215-0366(21)00039-0","DOI":"10.1016\/S2215-0366(21)00039-0"},{"key":"e_1_3_2_37_1","volume-title":"Standard quality assessment criteria for evaluating primary research papers from a variety of fields","author":"Kmet L. M.","year":"2004","unstructured":"Kmet L. M., Cook L. S., Lee R. C. (2004). Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.12927\/hcq.2011.22077"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000093"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Leal A. Rosillon D. Mehnert A. Jarema M. Remington G. (2004). Healthcare resource utilization during 1-year treatment with long-acting injectable risperidone. Pharmacoepidemiology and Drug Safety 13(11) 811\u2013816.","DOI":"10.1002\/pds.978"},{"issue":"4","key":"e_1_3_2_41_1","first-page":"848","article-title":"Admission rates, drug attitudes, and psychiatric symptoms in patients of schizophrenia after switching from paliperidone palmitate once-monthly to oral antipsychotics","volume":"46","author":"Lee B. J.","year":"2021","unstructured":"Lee B. J. (2021). Admission rates, drug attitudes, and psychiatric symptoms in patients of schizophrenia after switching from paliperidone palmitate once-monthly to oral antipsychotics. Rawal Medical Journal, 46(4), 848\u2013853.","journal-title":"Rawal Medical Journal"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2020.18.2.303"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Li N. Zhuo J. M. Turkoz I. Mathews M. Feng Y. Tan W. (2019). A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opinion on Pharmacotherapy 20(16) 2033\u20132039. https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2019.1650022","DOI":"10.1080\/14656566.2019.1650022"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00815-y"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpsy.2017.08.001"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-00238-8"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2020.1737134"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00900-y"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200505000-00001"},{"key":"e_1_3_2_50_1","volume-title":"Joanna Briggs Institute reviewer\u2019s manual","author":"Moola S.","year":"2017","unstructured":"Moola S., Munn Z., Tufanaru C., Aromataris E., Sears K., Sfetcu R., Currie M., Qureshi R., Mattis P., Lisy K. (2017). Chapter 7: Systematic reviews of etiology and risk. In Aromataris E., Munn Z. (Eds.), Joanna Briggs Institute reviewer\u2019s manual (p. 5). The Joanna Briggs Institute."},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1571295"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.06.013"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2007.11.012"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12028ah1"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00980.x"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2019.17.4.531"},{"key":"e_1_3_2_57_1","doi-asserted-by":"crossref","unstructured":"Okoli C. T. C. Kappi A. Wang T. Makowski A. Cooley A. T. (2022). The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis. International Journal of Mental Health Nursing 31(3) 469\u2013535. https:\/\/doi.org\/10.1111\/inm.12964","DOI":"10.1111\/inm.12964"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148365-200806010-00004"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","unstructured":"Patel C. El Khoury A. Huang A. Wang L. Bashyal R. (2020). Healthcare resource utilization and costs among patients with schizophrenia switching from oral risperidone\/paliperidone to once-monthly paliperidone palmitate: A Veterans Health Administration claims analysis. Current Therapeutic Research 92 100587. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7378858\/pdf\/main.pdf","DOI":"10.1016\/j.curtheres.2020.100587"},{"key":"e_1_3_2_61_1","doi-asserted-by":"crossref","unstructured":"Patel C. Emond B. Lafeuille M.-H. C\u00f4t\u00e9-Sergent A. Lefebvre P. Tandon N. El Khoury A. C. (2020). Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate. Drugs-Real World Outcomes 7(1) 19\u201329. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7061019\/pdf\/40801_2019_Article_172.pdf","DOI":"10.1007\/s40801-019-00172-9"},{"key":"e_1_3_2_62_1","first-page":"9","article-title":"Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia","volume":"3","author":"Peng X.","year":"2011","unstructured":"Peng X., Ascher-Svanum H., Faries D., Conley R. R., Schuh K. J. (2011). Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. ClinicoEconomics and Outcomes Research: CEOR, 3, 9\u201314.","journal-title":"ClinicoEconomics and Outcomes Research: CEOR"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S199048"},{"issue":"563","key":"e_1_3_2_64_1","first-page":"316","article-title":"Fluphenazine decanoate maintenance in schizophrenia: A retrospective study","volume":"83","author":"Polonowita A.","year":"1976","unstructured":"Polonowita A., James N. M. (1976). Fluphenazine decanoate maintenance in schizophrenia: A retrospective study. The New Zealand Medical Journal, 83(563), 316\u2013318.","journal-title":"The New Zealand Medical Journal"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2010.01211.x"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599080-000000000-00000"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30264-9"},{"key":"e_1_3_2_68_1","doi-asserted-by":"crossref","unstructured":"Sajatovic M. Ross R. Legacy S. N. Correll C. U. Kane J. M. DiBiasi F. Fitzgerald H. Byerly M. (2018a). Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics\u2013expert consensus survey part 1. Neuropsychiatric Disease and Treatment 14 1463\u20131474. https:\/\/doi.org\/10.2147\/NDT.S167394","DOI":"10.2147\/NDT.S167394"},{"key":"e_1_3_2_69_1","doi-asserted-by":"crossref","unstructured":"Sajatovic M. Ross R. Legacy S. N. Byerly M. Kane J. M. DiBiasi F. Fitzgerald H. Correll C. U. (2018b). Initiating\/maintaining long-acting injectable antipsychotics in schizophrenia\/schizoaffective or bipolar disorder\u2014Expert consensus survey part 2. Neuropsychiatric Disease and Treatment 14 1475\u20131492. https:\/\/doi.org\/10.2147\/NDT.S167485","DOI":"10.2147\/NDT.S167485"},{"key":"e_1_3_2_70_1","doi-asserted-by":"crossref","unstructured":"Schmauss M. Sacchetti E. Kahn J. P. Medori R. (2007). Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. International Clinical Psychopharmacology 22(2) 85\u201392. https:\/\/doi.org\/10.1097\/YIC.0b013e3280119ddb","DOI":"10.1097\/YIC.0b013e3280119ddb"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.100.2.571-574"},{"issue":"1","key":"e_1_3_2_72_1","first-page":"32","article-title":"A subgroup analysis of Chinese patients switched to paliperidone palmitate one-month injectable by prior oral antipsychotic treatment","volume":"49","author":"Si T.","year":"2016","unstructured":"Si T., Fan J., Wang X., Wang C., Xu C., Zhuo J., Feng Y. (2016). A subgroup analysis of Chinese patients switched to paliperidone palmitate one-month injectable by prior oral antipsychotic treatment. Pharmacopsychiatry, 49(1), 32\u201341.","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"e_1_3_2_73_1","first-page":"237","article-title":"The effect of switching to Long-Acting Injection (LAI) antipsychotic therapy on patients with schizophrenia","volume":"47","author":"Strunoiu L. M.","year":"2021","unstructured":"Strunoiu L. M., Du\u0163escu M. M., Strunoiu C. M., Alexandru D. O., P\u00eerlog M. C., Tica A. A. (2021). The effect of switching to Long-Acting Injection (LAI) antipsychotic therapy on patients with schizophrenia. Current Health Sciences Journal, 47(2), 237\u2013248.","journal-title":"Current Health Sciences Journal"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00643.x"},{"issue":"4","key":"e_1_3_2_75_1","first-page":"214","article-title":"The use of fluphenazine decanoate (Modecate) depot therapy in outpatient schizophrenics: A retrospective study","volume":"22","author":"Tan C. T.","year":"1981","unstructured":"Tan C. T., Ong T. C., Chee K. T. (1981). The use of fluphenazine decanoate (Modecate) depot therapy in outpatient schizophrenics: A retrospective study. Singapore Medical Journal, 22(4), 214\u2013218.","journal-title":"Singapore Medical Journal"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/0364-7722(81)90008-4"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2020.06.013"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.07.025"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-009-0215-9"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00713-9"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S77778"},{"key":"e_1_3_2_82_1","doi-asserted-by":"crossref","unstructured":"Zhdanava M. Lin D. Lafeuille M.-H. Ghelerter I. Morrison L. Lefebvre P. Joshi K. (2021). Antipsychotic adherence resource use and costs before and after the initiation of once-monthly paliperidone palmitate therapy among medicaid beneficiaries with prior schizophrenia relapse. Clinical Therapeutics 43(3) 535\u2013548. https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.011","DOI":"10.1016\/j.clinthera.2021.01.011"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S309768"}],"container-title":["Journal of the American Psychiatric Nurses Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10783903241279605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10783903241279605","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10783903241279605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:44:37Z","timestamp":1777491877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10783903241279605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/10783903241279605"],"URL":"https:\/\/doi.org\/10.1177\/10783903241279605","relation":{},"ISSN":["1078-3903","1532-5725"],"issn-type":[{"value":"1078-3903","type":"print"},{"value":"1532-5725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}